U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. Allergenics
  4. January 22, 2015 Approval Letter - ORALAIR
  1. Allergenics

January 22, 2015 Approval Letter - ORALAIR

Our STN BL: 125471/18

Stallergenes, Inc.
Attention: Thomas A. Lang, Ph.D.
600 Cordwainer Drive
Suite A
Norwell, MA 02061

Dear Dr. Lang:

We have approved your request to supplement your biologics license application for Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extractmanufactured at your, Antony, France, facility, to revise the blister and carton labeling with updated safety information.

The changes to the blister and carton labeling include revised proper name, dosage form, and route of administration to be in sentence case for better readability and appropriate prominence, revised green to black wording on the blisters to give the wording more prominence against a foil background, and the “Not for Resale” wording on the sample cartons has been revised to, “Not for Sale.”

Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.  In addition, please submit three original paper copies for carton and container final printed labeling.  All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.

In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, Food and Drug Administraion, Silver Spring, MD 20993. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253
(21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims
(21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that include these changes.

We will include the information contained in the above referenced supplement in your Biologics License Application file.

Sincerely yours,

Wellington Sun, M.D.
Division of Vaccine and
Related Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling